Neuroscience Partnerships

We are determined to bring transformative treatments to people living with Multiple Sclerosis (MS), Parkinson’s disease, tauopathies, Amyotrophic Lateral Sclerosis (ALS), and Huntington’s disease. 
Dov, Multiple Sclerosis, IsraelDov, Multiple Sclerosis, Israel

Our neuroscience goals

We focus on modulating neuroinflammation, facilitating neuroprotection, repair, and remyelination in neurological diseases, and slowing down or halting neurodegeneration.

Neurons sending pulsating electric impulsesNeurons sending pulsating electric impulses

A shared commitment

We partner with companies that share our commitment and bring expertise in translational neuroscience and technologies.

Partnering success stories

Denali Therapeutics

We’re collaborating to develop RIPK1 inhibitors for potential treatments of neurological and inflammatory diseases, such as Alzheimer’s, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis. 


We’re collaborating to develop a potential first-in-class, bi-specific alpha-synuclein antibody for Parkinson’s disease. It’s designed as a “brain shuttle” that targets insulin-like growth factor 1 receptors.

Your partnering leads in Neuroscience

For more information, contact us at

Brian Bronk

Brian Bronk

Global Head of Business Development, Neurology, Rare Diseases & Technology Platforms

Guy Griebel

Guy Griebel

Head of External Innovation, Rare and Neurological Disorders

Oncology Partnerships